博雅生物：获得破伤风人免疫球蛋白药品注册证书

Core Viewpoint - The company has received a drug registration certificate for Tetanus Human Immunoglobulin from the National Medical Products Administration, which enhances its product pipeline and boosts research and development enthusiasm [1] Group 1 - The drug registration certificate number is 2025S03488 [1] - The Tetanus Human Immunoglobulin is in injectable form, with a specification of 250 IU of tetanus antibodies per vial (2.5 ml) [1] - This approval is expected to enrich the company's product offerings [1]